American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Sacituzumab govitecan (SG) showed a significant survival benefit over single-agent chemotherapy treatment of physician’s choice (TPC) in the pivotal phase 3 ASCENT trial. Read More ›

Wrap-Up

Revised Overall Survival and Progression-Free Survival Data from the FAKTION Study: Capivasertib + Fulvestrant in Metastatic, ER-Positive Breast Cancer

ASCO 2022 – Wrap-Up

Capivasertib plus fulvestrant’s PFS advantage benefitted a broader patient population, and overall survival (OS) data with improved biomarker analyses can now be reported. Read More ›

Assessment of Oncology Patient Satisfaction with Telehealth Visits

ASCO 2021 – Breast Cancer

Telehealth visits provide increased access to care for oncology patients across multiple demographics with reported high patient satisfaction with level of care. Read More ›

Wrap-Up

Weight Gain in Breast Cancer Patients During Adjuvant Endocrine Therapy Linked to Menopausal Status

ASCO 2021 – Breast Cancer: Wrap-Up

Improved understanding of potential risk factors associated with weight gain will allow identification of at-risk patients and intervention for improved outcomes. Read More ›

Wrap-Up

Telemedicine Program Provides High-Quality Anticancer Medication Delivery and Management for Veterans

ASCO 2021 – Breast Cancer: Wrap-Up

The VA CARES program provides coordinated cancer care for veterans prescribed oral antineoplastic therapies who may lack access to comprehensive medication management resources. Read More ›

Wrap-Up

Real-Life Study of Alpelisib plus Fulvestrant Therapy After Treatment with CDK4/6 Inhibitor in French Breast Cancer Patients

ASCO 2021 – Breast Cancer: Wrap-Up

Alpelisib plus fulvestrant combination therapy improves progression-free survival while maintaining effectiveness in patients with HR-positive/HER2-negative advanced breast cancer in a French early access study. Read More ›

Wrap-Up

Implications for Use of Subjective Social Status as a Risk Factor for Metabolic Syndrome in Black Women with New Breast Cancer Diagnosis

ASCO 2021 – Breast Cancer: Wrap-Up

Metabolic syndrome is associated with poor prognosis in patients with breast cancer. Identifying potential risk factors for metabolic syndrome may improve outcomes in these women. Read More ›

Inflammatory Responses to Neoadjuvant Chemotherapy Can Be Regulated by Moderate Physical Exercise Prior to Surgery

ASCO 2021 – Breast Cancer

Moderate physical activity reduced the inflammatory response triggered by neoadjuvant chemotherapy in breast cancer patients prior to surgery. The benefit appears to be lost after surgery. Read More ›

Assessment of Factors That Influence Psychosocial Function in Breast Cancer Patients After Treatment

ASCO 2021 – Breast Cancer

Diverse factors contribute to shifts in psychosocial function in breast cancer patients after treatment. Understanding these factors provides opportunities for patients to receive more holistic care. Read More ›

Identification of Biomarkers for HER2-Negative Advanced Breast Cancer Is Influenced by Race: A Real-World Study

ASCO 2021 – Breast Cancer

Actionable biomarkers associated with directed treatment to prevent or reverse symptoms in African Americans with advanced-stage breast cancer may reduce mortality rates. Read More ›

American Society of Clinical Oncology (ASCO)

Page 3 of 29